Department of Chemistry, Southern Methodist University, Dallas, TX 75205, USA.
MATFab Facility, The University of Iowa, Iowa City, IA 52242, USA.
Int J Pharm. 2023 Nov 25;647:123516. doi: 10.1016/j.ijpharm.2023.123516. Epub 2023 Oct 19.
Thiabendazole is an anthelmintic drug used to treat strongyloidiasis (threadworm), cutaneous and visceral larva migrans, trichinosis, and other parasites. The active pharmaceutical ingredient is typically administered orally as tablets that should be chewed before swallowing. Current formulations combine the active ingredient with excipients, including sodium saccharinate as a sweetener. Thiabendazole's low aqueous solubility hinders fast dissolution and absorption through the mucous membranes. We sought to reformulate this medicine to improve both solubility and palatability. We utilized the possibility of protonation of the azole nitrogen atom and selected four different hydrogen donors: saccharin, fumaric, maleic, and oxalic acids. Solvothermal synthesis resulted in salts with each co-former, whereas neat and liquid-assisted grinding enabled the synthesis of additional formulations. Product formation was observed by powder X-ray diffraction. To better understand the structural basis of the proton transfer, we solved the crystal structures of the salts with saccharin, maleic acid, and oxalic acid using single-crystal X-ray diffraction. The structure of the salt with fumaric acid was solved by powder X-ray diffraction. We further characterized the salts with vibrational spectroscopic and thermoanalytical methods. We report a broad tunability of the aqueous solubility of thiabendazole by salt formation. Reformulation with maleic acid provided a 60-fold increase in solubility, while saccharin and oxalic acid gave a modest improvement. Fumaric acid resulted in a solid with only slightly higher solubility. Furthermore, saccharin is a sweetener, while the acids taste sour. Therefore, the salts formed also result in an intrinsic improvement of palatability. These results can inform new strategies for oral and chewable tablet formulations for treating helminthic infections.
噻苯达唑是一种驱虫药,用于治疗旋毛虫病(线虫)、皮肤和内脏幼虫移行症、旋毛虫病和其他寄生虫。活性药物成分通常作为片剂口服给药,在吞咽前应咀嚼。目前的配方将活性成分与赋形剂结合在一起,包括糖精钠作为甜味剂。噻苯达唑的低水溶解度阻碍了通过粘膜的快速溶解和吸收。我们试图重新配方这种药物以提高其溶解度和可接受性。我们利用唑氮原子质子化的可能性,选择了四种不同的供氢体:糖精、富马酸、马来酸和草酸。溶剂热合成得到了与每种共晶形成剂的盐,而纯物质和液体辅助研磨则能够合成其他配方。通过粉末 X 射线衍射观察到产物形成。为了更好地理解质子转移的结构基础,我们使用单晶 X 射线衍射解析了与糖精、马来酸和草酸形成的盐的晶体结构。通过粉末 X 射线衍射解析了与富马酸形成的盐的结构。我们还使用振动光谱和热分析方法对盐进行了进一步表征。我们报告了通过盐形成来调节噻苯达唑水溶解度的广泛可调性。与马来酸的重新配方使溶解度提高了 60 倍,而糖精和草酸则略有改善。富马酸得到的固体溶解度仅略有提高。此外,糖精是一种甜味剂,而酸则有酸味。因此,形成的盐也导致内在的可接受性提高。这些结果可以为治疗蠕虫感染的口服和咀嚼片制剂提供新的策略。